Cost of innovation in the pharmaceutical industry.

Keywords

Business, Pharmaceutical industry, Point (geometry), Operations management, Marketing

References

• The Competitive Status of the U.S. Pharmaceutical Industry: The Influences of Technology in Determining International Industrial Competitive AdvantageLacy Glenn Thomas, Trade Issues. Pharmaceutical Panel, Technical Systems — 1983
• Conditional logit analysis of qualitative choice behaviorDaniel McFadden — 1972
• Success rates in the United States drug development systemLorraine E. Sheck, Christopher Cox, Henry T. Davis — 1984
• A closer look at the returns and risk of pharmaceutical R&D.Prafulla Joglekar, Morton L. Paterson — 1986
• Research and Development Costs and Returns: The U.S. Pharmaceutical IndustryMartin Neil Baily — 1972
• Development Cost: Determinants and OverrunsJerome Schnee — 1972
• A sensitivity analysis of expected profitability of pharmaceutical research and developmentHenry G. Grabowski, John M. Vernon — 1982
• New drug development in the United States, 1963 through 1984Nancy Mattison, A Gene Trimble, Louis Lasagna — 1988
• Price indexes for R and D inputs 1969-1983Edwin Mansfield — 1987
• Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical IndustryHenry G. Grabowski, John M. Vernon, Lacy Glenn Thomas — 1978
• The Economics of Drug InnovationRobert W. Hammel — 1971
• A New Look at the Returns and Risks to Pharmaceutical R&DHenry G. Grabowski, John M. Vernon — 1990
• Impact of Regulations on Industrial R&D : FDA Regulations and Their Influence on Future R&D : R&D ManagementLewis H. Sarett — 1974
• NEW DRUG DEVELOPMENT IN THE UNITED STATES — THE FACTS AND FIGURES1978
• Innovation and International Competitiveness in PharmaceuticalsH. Grabowski — 1990
• QUALITATIVE RESPONSE MODELS: A SURVEYTakeshi Amemiya — 1981

Cited by

• New drug development in the United States from 1963 to 1992Santiago Bellés Medall — 1994
• Financial Analysts impact on Stock VolatilityClara Isabel González Martínez, Ricardo Gimeno — 2012
• From Norway to Novartis: cyclosporin from Tolypocladium inflatum in an open access bioprospecting regimeHanne Svarstad, Hans Chr. Bugge, Shivcharn S. Dhillion — 2000
• Accounting- versus economic-based rates of return: implications for profitability measures in the pharmaceutical industry.James A. Tompkins — 2004
• The changing structure of the pharmaceutical industry.Luis Martín Estudillo — 2004
• A Model of Effective Health PolicyGuy-Alain Amoussou, Steven J. Steinberg — 2003
• Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse EventsGaetano Antonio Lanza, Mariano Strano, Marion Calandra — 2016
• Valuation of medicinal plants for pharmaceutical usesPushpam Kumar — 2004
• Assessing the FDA Via the Anomaly of Off-Label PrescribingAlexander Tabarrok — 2000
• Technology Trends in Drug Discovery and Development: Implications for the Development of the Pharmaceutical Industry in AustraliaKim Sweeny — 2002
• Candidate cancer-targeting agents identified by expression-profiling arraysApiwat Mutirangura, Vittavat Termglinchan, Wanichnopparat — 2013
• Knowledge accumulation and vaccine innovation: lessons from polio and HIV/AIDSOhid Yaqub — 2010
• Which form of venture capital is most supportive of innovation? Evidence from European biotechnology companiesFabio Bertoni, Tereza Tykvová — 2012
• Security market reaction to FDA fast track designations.Christopher W. Anderson, Ying Zhang — 2010
• Valuation of a Biotechnology Firm: An application of real-options methodologiesD. W. Kellogg, John M. Charnes, Rıza Demirer — 1999
• A dynamic simulation framework for biopharmaceutical capacity managementP. Ashouri — 2011
• Update on the antibacterial resistance crisis.Arthur C. Croft, Anthony V. D’Antoni, Stephanie Terzulli — 2007
• Valuation Techniques: Discounted Cash Flow, Earnings Quality, Measures of Value Added, and Real OptionsLarrabee — 2012
• Research Productivity in the Japanese Pharmaceutical Industry: Economies of Scale, Economies of Scope and SpilloversYosuke Okada, Akihiro Kawara — 2004
• The antiplasmodial activities of the tetramethylpiperidyl-substituted phenazines, B4119 and B4158M. Makgatho — 1999

Related papers

• Competition in the Pharmaceutical IndustryBianca Piachaud — 2004
• The Importance Of Research And Development In The Syrian Pharmaceutical IndustryNoureddine Hormuz, Ola Ebraheem — 2020
• Facts, Fiction, and the Pharmaceutical IndustryJohn Lloyd Hanson — 1986
• The Direction of Pharmaceutical Industry's Development and Integration under the New Medical ReformKong Xiang-ji — 2009
• An Overview of the Global Pharmaceutical IndustryBianca Piachaud — 2004